PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis

Journal of Hepatology

Volumn 66, Issue 3, 2017, Pages 589-600

  Mukhopadhyay, Partha ^a   Horváth, Béla ^a   Rajesh, Mohanraj ^a   Varga, Zoltán V ^a   Gariani, Karim ^b   Ryu, Dongryeol ^b   Cao, Zongxian ^a   Holovac, Eileen ^a   Park, Ogyi ^a   Zhou, Zhou ^a   Xu, Ming Jiang ^a   Wang, Wei ^a   Godlewski, Grzegorz ^a   Paloczi, Janos ^a   Nemeth, Balazs Tamas ^a   Persidsky, Yuri ^c   Liaudet, Lucas ^d   Haskó, György ^e   Bai, Peter ^f,g   Boulares, A Hamid ^h   Auwerx, Johan ^b   Gao, Bin ^a   Pacher, Pal ^a   more..

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b EPFL   (Switzerland)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF DEBRECEN   (Hungary)

^g MTA DE Lendulet Laboratory of Cellular Metabolism   (Hungary)

^h LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohols; Fatty liver; Inflammation; Kupffer cells; Mitochondria; NAD+; NASH; Oxidative stress; Reactive oxygen species

Indexed keywords

AIQ; ALCOHOL; CHOLINE; FAT; LIVER PROTECTIVE AGENT; METHIONINE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FATTY ACID; N-(OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)-N,N-DIMETHYLACETAMIDE HYDROCHLORIDE; OLAPARIB; PARP1 PROTEIN, MOUSE; PHENANTHRENE DERIVATIVE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINOLINE DERIVATIVE; REL-(3S, 5R, 6S, SR, 8AR,12AR)-8-ACETOXY-6-BUTYL-3-ISOTHIOCYANATODECAHYDROPYRIDO(2,1)QUINOLINE; SIRT1 PROTEIN, MOUSE;

ALCOHOL CONSUMPTION; ALCOHOLIC FATTY LIVER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID METABOLISM; GENE ACTIVATION; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KUPFFER CELL; LIVER FIBROSIS; LIVER PROTECTION; MALE; METABOLIC DISORDER; MOUSE; NITRATIVE STRESS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIPID DIET; LIVER; METABOLISM; NITROSATIVE STRESS; PATHOLOGY;

ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY ACIDS; FATTY LIVER, ALCOHOLIC; HUMANS; KUPFFER CELLS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NAD; NITROSATIVE STRESS; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PHENANTHRENES; PHTHALAZINES; PIPERAZINES; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; QUINOLINES; SIRTUIN 1;

EID: 85007418088     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.10.023     Document Type: Article

References (32)

1. [1] Gao, B., Bataller, R., Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141 (2011), 1572–1585.
2. [2] Nagy, L.E., Ding, W.X., Cresci, G., Saikia, P., Shah, V.H., Linking pathogenic mechanisms of alcoholic liver disease with clinical phenotypes. Gastroenterology 150 (2016), 1756–1768.
3. [3] Lieber, C.S., Leo, M.A., Wang, X., Decarli, L.M., Effect of chronic alcohol consumption on Hepatic SIRT1 and PGC-1alpha in rats. Biochem Biophys Res Commun 370 (2008), 44–48.
4. [4] Szabo, G., Gut-liver axis in alcoholic liver disease. Gastroenterology 148 (2015), 30–36.
5. [5] Jagtap, P., Szabo, C., Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4 (2005), 421–440.
6. [6] Kraus, W.L., Hottiger, M.O., PARP-1 and gene regulation: Progress and puzzles. Mol Aspects Med 34 (2013), 1109–1123.
7. [7] Oliver, F.J., Menissier-de Murcia, J., Nacci, C., Decker, P., Andriantsitohaina, R., Muller, S., et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 18 (1999), 4446–4454.
8. [8] Bai, P., Nagy, L., Fodor, T., Liaudet, L., Pacher, P., Poly(ADP-ribose) polymerases as modulators of mitochondrial activity. Trends Endocrinol Metab 26 (2015), 75–83.
9. [9] Pacher, P., Beckman, J.S., Liaudet, L., Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87 (2007), 315–424.
10. [10] Curtin, N.J., Szabo, C., Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 34 (2013), 1217–1256.
11. [11] Mukhopadhyay, P., Rajesh, M., Cao, Z., Horvath, B., Park, O., Wang, H., et al. Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology 59 (2014), 1998–2009.
12. [12] Bertola, A., Mathews, S., Ki, S.H., Wang, H., Gao, B., Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc 8 (2013), 627–637.
13. [13] Canto, C., Houtkooper, R.H., Pirinen, E., Youn, D.Y., Oosterveer, M.H., Cen, Y., et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 15 (2012), 838–847.
14. [14] Bertola, A., Park, O., Gao, B., Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin. Hepatology 58 (2013), 1814–1823.
15. [15] Chang, B., Xu, M.J., Zhou, Z., Cai, Y., Li, M., Wang, W., et al. Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1. Hepatology 62 (2015), 1070–1085.
16. [16] Shiobara, M., Miyazaki, M., Ito, H., Togawa, A., Nakajima, N., Nomura, F., et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 16 (2001), 338–344.
17. [17] Gariani, K., Menzies, K.J., Ryu, D., Wegner, C.J., Wang, X., Ropelle, E.R., et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 63 (2016), 1190–1204.
18. [18] Nomura, F., Yaguchi, M., Itoga And, S., Noda, M., Effects of chronic alcohol consumption on hepatic poly-ADP-ribosylation in the rat. Alcohol Clin Exp Res 25 (2001), 35S–38S.
19. [19] Clerici, L., Sacco, M.G., Merlini, M., Acetaldehyde activation of poly(ADP-ribose)polymerase in hepatocytes of mice treated in vivo. Mutat Res 227 (1989), 47–51.
20. [20] Akinshola, B.E., Sharma, S., Potter, J.J., Mezey, E., Ethanol enhances ADP-ribosylation of protein in rat hepatocytes. Hepatology 15 (1992), 471–476.
21. [21] Gariani, K., Ryu, D., Menzies, K., Yi, H.S., Stein, S., Zhang, H., et al. Inhibiting poly-ADP ribosylation increases fatty acid oxidation and protects against fatty liver disease. J Hepatol 66 (2017), 132–141.
22. [22] Bode, C., Kugler, V., Bode, J.C., Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 4 (1987), 8–14.
23. [23] Bala, S., Marcos, M., Gattu, A., Catalano, D., Szabo, G., Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS One, 9, 2014, e96864.
24. [24] Cunningham, C.C., Coleman, W.B., Spach, P.I., The effects of chronic ethanol consumption on hepatic mitochondrial energy metabolism. Alcohol Alcohol 25 (1990), 127–136.
25. [25] Bailey, S.M., Cunningham, C.C., Contribution of mitochondria to oxidative stress associated with alcoholic liver disease. Free Radical Biol Med 32 (2002), 11–16.
26. [26] Moon, K.H., Hood, B.L., Kim, B.J., Hardwick, J.P., Conrads, T.P., Veenstra, T.D., et al. Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats. Hepatology 44 (2006), 1218–1230.
27. [27] Lieber, C.S., Leo, M.A., Wang, X., Decarli, L.M., Alcohol alters hepatic FoxO1, p53, and mitochondrial SIRT5 deacetylation function. Biochem Biophys Res Commun 373 (2008), 246–252.
28. [28] Haigis, M.C., Sinclair, D.A., Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5 (2010), 253–295.
29. [29] Houtkooper, R.H., Auwerx, J., Exploring the therapeutic space around NAD+. J Cell Biol 199 (2012), 205–209.
30. [30] Caron, A.Z., He, X., Mottawea, W., Seifert, E.L., Jardine, K., Dewar-Darch, D., et al. The SIRT1 deacetylase protects mice against the symptoms of metabolic syndrome. FASEB J 28 (2014), 1306–1316.
31. [31] Yin, H., Hu, M., Liang, X., Ajmo, J.M., Li, X., Bataller, R., et al. Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling and aggravates alcoholic fatty liver. Gastroenterology 146 (2014), 801–811.
32. [32] Xu, F., Gao, Z., Zhang, J., Rivera, C.A., Yin, J., Weng, J., et al. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: a role of lipid mobilization and inflammation. Endocrinology 151 (2010), 2504–2514.